Advertisement


Fatima Karzai, MD, on Prostate Cancer: Treatment Study Results

2018 Genitourinary Cancers Symposium

Advertisement

Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).



Related Videos

Kidney Cancer
Immunotherapy

Sumanta K. Pal, MD, on RCC: Results From Two Clinical Trials

Sumanta K. Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase III study findings from IMmotion151, which looked at atezolizumab plus bevacizumab vs sunitinib...

Solid Tumors

Jeffrey M. Holzbeierlein, MD, on Penile, Urethral, and Testicular Cancers: Abstract Roundup

Jeffrey M. Holzbeierlein, MD, of the University of Kansas Medical Center, summarizes key abstracts on long-term sexual function in germ cell tumor survivors, sentinel node biopsy i...

Bladder Cancer
Immunotherapy

Thomas Powles, MD, on Urothelial Carcinoma: Results From the IMvigor211 Trial

Thomas Powles, MD, of Barts Cancer Institute, discusses phase III study findings on atezolizumab vs chemotherapy in platinum-treated locally advanced or metastatic urothelial carci...

Kidney Cancer

Daniel J. George, MD, on RCC: Study Results on Adjuvant Treatment

Daniel J. George, MD, of Duke University Medical Center, discusses phase III findings on adjuvant sunitinib in patients with high-risk renal cell carcinoma, in an exploratory pharm...

Kidney Cancer

Patrick Schöffski, MD, MPH, on RCC: Final Results of the EORTC 90101 CREATE Trial

Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinom...

Advertisement

Advertisement



;
Advertisement